对Empagliflozin对脏和全身血动力学影响的随机,安慰剂控制试验
Steffen Flindt Nielsen1,2, Camilla Lundgreen Duus1,2, Niels Henrik Buus2,3
1University Clinic in Nephrology and Hypertension, Gødstrup Hospital, Denmark.
Kidney international reports
|January 15, 2025
概括
-葡萄糖携带载体2抑制剂 (SGLT2i) 降低了2型糖尿病和慢性病患者的血液流动. 这些发现表明,SGLT2i通过结合的前球和后球效应,为球提供保护.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
背景情况:
- -葡萄糖共运输体2抑制剂 (SGLT2i) 是在2型糖尿病 (DM2) 和慢性病 (CKD) 中确定的保护剂.
- 基于SGLT2i对脏的益处的机制可能涉及脏血液动力学变化,包括脏血流 (RBF) 和球过率 (GFR).
研究的目的:
- 研究SGLT2抑制剂在患有DM2和CKD的患者中对脏和全身血动力学特异性的影响.
- 为了在功能不同阶段和非糖尿病慢性病患者中比较这些影响.
主要方法:
- 采用双盲,安慰剂控制,交叉研究设计.
- 患有DM2 (eGFR>60或20-60毫升/分钟/1.73米2) 和非糖尿病CKD (eGFR20-60毫升/分钟/1.73米2) 的患者接受了empagliflozin 10 mg或安慰剂4周,随后进行了为期2周的洗和交叉.
- 使用82Rubidium-PET/CT评估血流 (RBF),使用99mTechnetium-DTPA清除评估GFR,使用Mobil-O-graph评估24小时血压 (BP) 和总血管阻力 (TVR).
主要成果:
- 在患有DM2和CKD的患者中,empagliflozin显著减少了6%的RBF (P<0.001),仅在DM2和CKD组中没有显著的减少.
- 在所有患者群体中,empagliflozin降低了GFR,BP和TVR.
- 血管抵抗 (RVR) 在所有组中保持不变.
结论:
- 在DM2和CKD患者中,empagliflozin显然可以降低RBF,同时在所有研究组中降低GFR,BP和TVR.
- 观察到的血液动力学变化,特别是不变的RVR,表明SGLT2抑制剂通过结合的前球和后球机制对球产生保护作用.
相关概念视频
01:33Hormonal Regulation
32.9K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
132
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
132
01:17Factors Affecting Renal Clearance: Renal Impairment
52
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
52
01:01Feedback Loops
55.8K
In most cases, excessive hormone production is prevented by negative feedback—a loop that starts with a stimulus inducing the release of a particular substance, like a hormone, to maintain a certain level before triggering a signal that results in a decrease in further release of the hormone.
55.8K
01:31Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
167
Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
167